Private Wealth Partners LLC Sells 18,631 Shares of Boston Scientific Corporation $BSX

Private Wealth Partners LLC cut its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 8.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,436 shares of the medical equipment provider’s stock after selling 18,631 shares during the period. Boston Scientific comprises approximately 1.7% of Private Wealth Partners LLC’s investment portfolio, making the stock its 19th largest holding. Private Wealth Partners LLC’s holdings in Boston Scientific were worth $22,066,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Howard Capital Management Inc. lifted its stake in Boston Scientific by 31.5% during the 2nd quarter. Howard Capital Management Inc. now owns 10,753 shares of the medical equipment provider’s stock valued at $1,155,000 after acquiring an additional 2,576 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Boston Scientific by 24.0% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 287,958 shares of the medical equipment provider’s stock worth $30,930,000 after purchasing an additional 55,800 shares during the period. Advisory Alpha LLC raised its stake in shares of Boston Scientific by 14.3% during the 2nd quarter. Advisory Alpha LLC now owns 6,859 shares of the medical equipment provider’s stock worth $737,000 after purchasing an additional 860 shares during the period. SYM FINANCIAL Corp bought a new stake in shares of Boston Scientific during the 2nd quarter worth $202,000. Finally, Wealth Watch Advisors INC bought a new stake in shares of Boston Scientific during the 2nd quarter worth $186,000. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 167,313 shares of company stock valued at $17,237,959 in the last ninety days. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.3%

BSX stock opened at $102.43 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $151.77 billion, a PE ratio of 54.77, a PEG ratio of 2.04 and a beta of 0.61. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The stock has a 50-day simple moving average of $101.13 and a two-hundred day simple moving average of $102.16.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research note on Monday, September 29th. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a report on Wednesday, October 22nd. Weiss Ratings reissued a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Truist Financial lifted their price objective on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Leerink Partners lifted their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.